Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer. A comparison of different schedules and treatments by Del Mastro, L. et al.
Del Mastro et al. BMC Cancer 2013, 13:164
http://www.biomedcentral.com/1471-2407/13/164RESEARCH ARTICLE Open AccessRandomised phase 3 open-label trial of first-line
treatment with gemcitabine in association with
docetaxel or paclitaxel in women with metastatic
breast cancer: a comparison of different
schedules and treatments
Lucia Del Mastro1*, Alessandra Fabi2, Mauro Mansutti3, Michele De Laurentiis4,5, Antonio Durando6,
Domenico Franco Merlo7, Paolo Bruzzi7, Ignazia La Torre8, Matteo Ceccarelli8, Gbenga Kazeem9, Paolo Marchi8,
Davide Boy8, Marco Venturini10, Sabino De Placido4 and Francesco Cognetti2Abstract
Background: This open-label study compared docetaxel/gemcitabine vs. paclitaxel/gemcitabine and a weekly (W)
vs. 3-weekly (3 W) schedule in metastatic breast cancer (MBC).
Methods: Patients relapsed after adjuvant/neoadjuvant anthracycline-containing chemotherapy were randomized
to: A) gemcitabine 1000 mg/m2 Day 1,8 + docetaxel 75 mg/m2 Day 1 q3W; B) gemcitabine 1250 mg/m2 Day 1,8 +
paclitaxel 175 mg/m2 Day 1 q3W; C) gemcitabine 800 mg/m2 Day 1,8,15 + docetaxel 30 mg/m2 Day 1,8,15 q4W;
D) gemcitabine 800 mg/m2 Day 1,15 + paclitaxel 80 mg/m2 Day 1,8,15 q4W. Primary endpoint was time-to-progression
(TTP). Secondary endpoints were overall survival (OS) and overall response rate (ORR).
Results: Interim analysis led to accrual interruption (241 patients enrolled of 360 planned). Median TTP (months) was
8.33 (95% CI: 6.19-10.16) with W and 7.51 (95% CI: 5.93-8.33) with 3 W (p=0.319). No differences were observed in
median TTP between docetaxel and paclitaxel, with 85.6% and 87.0% of patients progressing, respectively. OS did not
differ between regimens/schedules. ORR was comparable between regimens (HR: 0.882; 95% CI: 0.523-1.488; p=0.639),
while it was significantly higher in W than in the 3 W (HR: 0.504; 95% CI: 0.299-0.850; p=0.010) schedule. Grade 3/4
toxicities occurred in 69.2% and 71.9% of patients on docetaxel and paclitaxel, and in 65.8% and 75.2% in W and 3 W.
Conclusions: Both treatment regimens showed similar TTP. W might be associated with a better tumour response
compared with 3 W.
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Approximately 4%-6% of breast cancer is metastatic at
diagnosis and, depending on prognostic factors, up to
30% of node negative and 70% of node positive breast
cancer will relapse [1]. Although the vast majority of
metastatic breast cancer cases are incurable, the main
goal of treatment is not only palliation but also survival
improvement. Chemotherapy is the cornerstone of ther-
apy for patients not candidates for endocrine therapy.
The widespread inclusion of anthracyclines in the adju-
vant setting limits their use as first-line therapy in meta-
static disease. Cytotoxic drugs with activity in advanced
breast cancer include the taxanes (paclitaxel and docetaxel),
gemcitabine, vinorelbine and capecitabine. The doublet
of paclitaxel and gemcitabine is superior in terms of
overall survival to monotherapy with paclitaxel [2]. Also
the combination of docetaxel and capecitabine is superior
to monotherapy but produced significant toxicity [3]. The
regimen of gemcitabine plus docetaxel showed similar
activity but less toxicity compared to capecitabine plus
docetaxel [4]. No direct comparisons between these two
doublets (gemcitabine plus paclitaxel and gemcitabine
plus docetaxel) are available so far.
Both paclitaxel and docetaxel can be administered as
weekly or three-weekly regimens and, at the time of the
study design, the most suitable regimen was still unknown.
Based on this background, the present Phase III trial
was designed to compare the two doublets docetaxel/
gemcitabine and paclitaxel/gemcitabine in terms of effi-
cacy and safety, as well as the use of a weekly schedule
over a standard 3-weekly regimen.Table 1 Main inclusion and exclusion criteria for entry in the
Inclusion criteria
Adult women with HER-2 negative MBC Prev
MBC relapsed after receiving one adjuvant/neoadjuvant chemotherapy
containing an anthracycline, unless clinically contraindicated
Prev
Could have received a prior neoadjuvant or adjuvant taxanes regimen
as long as it was ≥12 months since completion of the treatment
Patie
the
or o
of re
Measurable disease as defined by RECIST 1.0 (however patients with
only bone metastases were included in the study),
Pre-
Previous hormonal therapy for adjuvant setting or metastatic disease
(≤2 lines), or immunotherapy, was allowed and should have been
completed before the enrolment
Infla
Performance status ≥70 on the Karnofsky Scale Patie
activ
prec
Life expectancy ≥12 weeks Patie
Adequate bone marrow and liver/renal function Preg
Prior radiotherapy should have been completed 4 weeks before study entry Patie
met
HER-2: Human Epidermal Growth Factor Receptor 2, MBC: Metastatic Breast Cancer,
Evaluation Criteria in Solid Tumours.Methods
Patients
The study population included adult women with Hu-
man Epidermal Growth Factor Receptor 2 (HER-2) nega-
tive MBC who relapsed after receiving one adjuvant/
neoadjuvant chemotherapy treatment containing an anthra-
cycline, unless clinically contraindicated. Table 1 summa-
rizes the main inclusion and exclusion criteria for entry
in the study.
The participant patients gave their written informed
consent prior to entering the study. The study protocol
and the informed consent forms were reviewed and ap-
proved by the Independent Ethics Committees of each
participating centre before any study-related procedure
was started.
Study design and treatments
This was a multi-centre, open-label, 2x2 factorial random-
ised study (clinicaltrial.gov ID: NCT00236899) in which
eligible patients were equally randomised (using random-
number table with “investigational centre” as stratification
factor) to one of the following four treatment arms: Arm
A: gemcitabine 1000 mg/m2 administered intravenously
(IV) on Days 1 and 8 + docetaxel 75 mg/m2 IV on Day 1
of each 21-day cycle (3-weekly); Arm B: gemcitabine
1250 mg/m2 IV on Days 1 and 8 + paclitaxel 175 mg/m2
IV on Day 1 of each 21-day cycle (3-weekly); Arm C:
gemcitabine 800 mg/m2 IV on Days 1, 8 and 15 +
docetaxel 30 mg/m2 IV on Days 1, 8 and 15 of each
28-day cycle (weekly); Arm D: gemcitabine 800 mg/m2study
Exclusion criteria
ious chemotherapy for metastatic disease
ious chemotherapy with gemcitabine in any setting of disease
nts with second primary malignancy (except in situ carcinoma of
cervix or adequately treated non-melanoma carcinoma of the skin
ther malignancy treated at least 5 years previously with no evidence
currence)
existing sensorial or motor neuropathy NCI-CTC grade >1
mmatory breast cancer without evidence of metastatic disease
nts with serious concomitant systemic disorders (e.g., uncontrolled
e cardiovascular diseases and/or myocardial infarction within the
eding 6 months)
nts with clinical evidence of symptomatic brain metastasis
nancy or breast-feeding
nts with reproductive potential not using an approved contraceptive
hod if appropriate (except hormonal substitutive therapy)
NCI-CTC: National Cancer Institute-Common Toxicity Criteria, RECIST: Response
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8 and 15 of each 28-day cycle (weekly).
A maximum of 6 cycles was scheduled in case of
stable disease (SD, defined as neither sufficient shrinkage
to qualify for partial response nor suffiecient increase to
qualify for progression taking as reference the smallest
sum of the longest diameters since the treatment started),
to be continued up to 10 cycles for observed partial or
complete response, respectively. Patients were to be
discontinued from the study in the case of evidence of
progressive disease or unacceptable toxicity.
Dose adjustments were made based on the worst NCI-
common toxicity criteria (NCI-CTC version 3.0), toxicity
experienced by the patient in the previous cycle. Any
patient with two prior dose reductions who experienced
a toxicity that would cause a third dose reduction had
to be discontinued from study therapy.
No other chemotherapy, biological therapy, immunother-
apy (such as trastuzumab), hormonal therapy (excluding
corticosteroids) or experimental medications were per-
mitted while patients were on the study. Bisphosphonate
therapy was allowed at the discretion of the investigator.
Palliative radiation on painful lesions was allowed, pro-
vided that at least 2 weeks elapsed between the use of
gemcitabine and radiotherapy. Patients could receive
growth factors for hematologic toxicity, prophylactic anti-
emetics and/or premedication agents (e.g., corticosteroids).
Outcome measures
Tumour outcomes were evaluated every two cycles
according to RECIST 1.0 criteria. Time-to-progression
(TTP) was defined as the time from the first day of
treatment to first observation of documented disease
progression or death due to any cause. TTP was cen-
sored at the time of last follow-up for those patients
who were still alive without progression. Other efficacy
measures were overall survival (OS), defined as time
from enrolment to time of death as a result of any cause
(for patients still alive, OS was censored at the last con-
tact). Overall response rate (ORR) was evaluated every
two cycles according to RECIST 1.0 criteria. Best overall
response was the best response recorded from the start
of treatment until disease progression; complete and
partial responses (CR/PR) were to be confirmed by two
evaluations of the disease, taken at least 4 weeks apart;
stable disease (SD) was accepted if one measurement
was provided at least 9 weeks from baseline.
Safety analyses included summary of adverse event
rates and laboratory changes, summary of the number of
the NCI-CTC (version 3.0) toxicities grade for laboratory
and non-laboratory parameters. Toxicity was evaluated
on Day 1 of every cycle and at 30 days post study. On-
study evaluation of haematology occurred on Days 1 and
8 in Arms A and B, and on Days 1, 8 and 15 of everycycle in arms C and D. Post therapy assessment of
haematology occurred not earlier than 30 days after
completion of the last treatment cycle.
Quality of Life (QoL) was measured on Day 1 of every
cycle and at 30 days post study, using the Rotterdam Symp-
tom Checklist (RSCL) [5]. The RSCL was assessed for each
patient no more than one week before entering the study,
every 3 to 4 weeks and at 30 days post therapy visit.
Statistical considerations
The primary objectives of the study were 1) to compare
TTP in patients with metastatic breast cancer (MBC)
treated with gemcitabine plus docetaxel to patients treated
with gemcitabine plus paclitaxel and 2) to compare TTP
in MBC patients treated with a weekly schedule to pa-
tients treated with the standard three-weekly schedule.
The planned sample size of 360 patients was chosen to
allow the observation of 252 events, which gives 80%
power of rejecting the null hypothesis of no difference
in TTP rates against an alternative hypothesis of a 30%
reduction in TTP rates between the treatment groups
(schedules or drugs) assuming a two-sided significance
level of 5%. These assumptions were based on a constant
rate of accrual of 120 patients per year over a 3-year period.
Analyses for TTP, OS and QoL were conducted on all
randomised patients according to the intent-to-treat (ITT)
principle. For tumour response rates and safety, analyses
were performed for all randomised patients who received
at least one dose of docetaxel, paclitaxel or gemcitabine.
For each of the time-to-event endpoints, Kaplan-Meier
curves were generated, and quartiles and point probabil-
ities were calculated. Interval estimates were obtained
using 95% CIs.
A multivariate Cox proportional hazard analysis that
used covariates that could influence the time-to-event
endpoints (i.e., presence/absence of visceral metastases,
menopausal status, prior adjuvant/neoadjuvant taxane ther-
apy, prior hormonal therapy, treatment schedule, treatment
drug) was performed for TTP and OS. Response rate and
95% CI were calculated. In the analysis of ORR, a multivari-
ate logistic regression analysis, which included the same
covariates as those of the Cox’s model, was also performed.
For the QoL measures, descriptive statistics (number of
response and percentages) were tabulated for each treat-
ment arm.
Safety analyses included summaries of the blood/platelet
transfusion required, summary of adverse events rates and
laboratory changes, summary of the number of the NCI-
CTC (version 3.0) toxicities grade for laboratory and non-
laboratory parameters.
Interim futility analysis
The slow rate of accrual in the trial prevented the comple-
tion of the planned patients’ enrolment within a reasonable
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performed to evaluate if the study should be stopped
early for futility. The interim futility analysis was based
on all events (progressions or deaths without docu-
mented progression) that occurred before 30 November
2008 (i.e., more than 3 years from the start of the trial).
With 100-110 events, the expectation was as follows:
i) If HR >1 was obtained, then there was a strong sup-
port for stopping patients’ accrual for futility; ii) If HR
<0.85 was observed, then the accrual should have con-
tinued as planned.
Results
Interim futility analysis
Two hundred and fifty-two patients entered the futility
analysis and 113 events (56%) were observed. This con-
stituted about 45% (113/252) of the planned number of
events. The HR for TTP comparisons was 1.06 (95% CI:
0.73-1.54) for the docetaxel arm versus paclitaxel treat-
ment arm and 1.04 (95% CI: 0.72-1.51) for the weekly
versus 3-weekly schedules comparison. Based on these
results, it was estimated that if the original alternative
hypothesis (HR= 0.7) was true and the study was brought
to its natural conclusion, the chance (that is, conditional
power) of observing a significant difference in favour of
the docetaxel arm was 16% and only 6% between the treat-
ment schedules. On the basis of the results of the futility
analyses, the two alternative hypotheses for the primaryFigure 1 Patients disposition and reasons for study discontinuation.endpoint were less likely than when the study was initiated
and, consequently, it was considered as not appropriate to
continue the patient accrual for the study.
Patient disposition and treatment compliance
Overall, 241 patients were enrolled between September
2005 and August 2010 and were randomised as follow: 60
patients (24.9%) in Arm A (3-weekly docetaxel/gemcitabine),
64 (26.6%) in Arm B (3-weekly paclitaxel/gemcitabine), 58
(24.1%) in Arm C (weekly docetaxel/gemcitabine) and 59
(24.5%) in Arm D (weekly paclitaxel/gemcitabine). Treat-
ment arms were balanced in accordance with the baseline
factor “investigational centre”. Patient disposition and
reasons for discontinuation are reported in Figure 1.
Table 2 shows the demographic and other baseline
characteristics of the study population. There were no
substantial differences between groups for age, meno-
pausal status, hormonal receptor status, use of previous
hormonal therapy and presence of visceral metastases,
while fewer patients in Arm C than in the other three
groups had received previous adjuvant/neoadjuvant taxane
therapy.
The median number of administered chemotherapy cy-
cles was 6 in all arms. Treatment-related discontinuations
occurred in 6.7%, 6.2%, 10.3% and 13.6% of patients in
Arms A, B, C and D, respectively, while almost 50% of dis-
continuations were due to lack of efficacy (see also Figure 1
for details).
Table 2 Demographic and other baseline characteristics
Arm A Arm B Arm C Arm D Overall
(N=60) (N=64) (N=58) (N=59) (N=241)
Age (years)
Median (Range) 58.5 (37-76) 57.5 (31-74) 56 (38-77) 55 (33-76) 57 (31-77)
N (%) N (%) N (%) N (%) N (%)
Ethnic Origin, N (%) Caucasian 58 (96.6) 63 (98.4) 58 (100) 59 (100) 238 (98.8)
African 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Asian 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Othera 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 1 (0.4)
Menopausal status, N (%) pre 19 (31.7) 17 (26.6) 16 (27.6) 21 (35.6) 73 (30.3)
post 41 (68.3) 47 (73.4) 42 (72.4) 38 (64.4) 168 (69.7)
Karnofsky Performance Status, N (%) Point
Able to care for self 70 0 (0.0) 0 (0.0) 2 (3.5) 2 (3.4) 4 (1.66)
Normal activity but requiring effort 80 5 (8.3) 3 (4.7) 5 (8.6) 7 (11.9) 20 (8.3)
Able to carry on normal activity 90 11 (18.3) 16 (25.0) 9 (15.5) 15 (25.4) 51 (21.2)
Normal 100 44 (73.3) 44 (68.8) 41 (70.7) 35 (59.3) 164 (68.0)
Not done 0 (0.0) 1 (1.56) 1 (1.72) 0 (0.0) 2 (0.8)
Hormonal receptor status, N (%) ER+ 44 (73.3) 47 (73.4) 39 (67.2) 46 (78.0) 176 (73.0)
PR+ 38 (63.3) 43 (67.2) 34 (58.6) 42 (71.2) 157 (65.1)
Previous hormonal therapy, N (%) Yes 44 (73.7) 48 (75.0) 40 (69.0) 46 (78.0) 178 (73.9)
No 16 (26.7) 16 (25.0) 17 (29.3) 13 (22.0) 62 (25.7)
Visceral metastases, N (%) Absence 19 (31.7) 19 (29.7) 16 (27.6) 23 (39.0) 77 (32.0)
Presence 41 (68.3) 45 (70.3) 42 (72.4) 36 (61.0) 164 (68.0
Previous adjuvant/neoadjuvant taxane therapyb, N (%) Yes 21 (35.0) 24 (37.5) 12 (20.7) 19 (32.2) 76 (31.5)
No 39 (65.0) 40 (62.5) 45 (77.6) 40 (67.8) 164 (68.0)
aOther: 1 Creole; b1 patient in Arm C had no record for previous hormonal therapy and adjuvant/neoadjuvant therapy.
Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with
weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.
PR: Partial Response.
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The summary results and Kaplan-Meier curves of TTP by
treatment schedule and by treatment drug are shown in
Figures 2 and 3, respectively. For the treatment schedule,
101 (86.3%) and 107 (86.3%) patients showed progression
in the weekly and 3-weekly treatment schedules, respect-
ively. The difference between the median TTP of the
two treatment groups was not statistically significant
(8.33 months (95% CI: 6.19-10.16) for the weekly sched-
ule group versus 7.51 months (95% CI: 5.93-8.33) for
the 3-weekly schedule; (HR: 1.15; 95% CI: 0.87-1.51;
p-value=0.319). From the Cox regression analysis, similar
results were obtained (HR: 1.14; 95% CI: 0.87-1.50;
p-value=0.345) when adjusted for treatment drug and
visceral metastases (the only covariate that signifi-
cantly influenced TTP [p-value=0.023]). For the TTP
comparison between the two treatment drugs assign-
ment, the number of patients who showed progres-
sion was 101 (85.6%) and 107 (87.0%) for docetaxel andpaclitaxel treatment groups, respectively. There was no
statistically significant difference in the median TTP
between the two treatment drugs group. Median TTP
was 7.74 months (95% CI: 5.57-9.80) and 7.80 months
(95% CI: 6.20-8.72), respectively for the docetaxel
and the paclitaxel group (HR: 1.16; 95% CI: 0.88-
1.52; p-value=0.302). From the Cox regression model,
similar results were obtained when adjusted for treat-
ment schedule and visceral metastases as covariates
(HR: 1.23; 95% CI: 0.93-1.62; p-value=0.150). Overall,
no difference in TTP was observed between the four
treatment arms (Figure 4).
The median OS was 21.11 months (95% CI: 17.28-
26.75) and 20.95 months (95% CI: 18.92-33.21) for the
weekly schedule and the 3-weekly schedule, respectively
and no statistically significant difference was observed
(HR: 0.98; 95% CI: 0.69-1.37; p-value=0.886). With regard
to the two doublets, the median OS was 19.11 months
(95% CI: 16.59-24.0) and 23.80 months (95% CI: 19.38-
Figure 2 Results of time-to-progression (TTP) by treatment schedule (Weekly vs. 3-Weekly). Number of patients still at risk for 3-weekly (1)
and weekly (2) treatment schedule are reported above the X axis.
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no statistically significant difference (HR: 1.01; 95% CI:
0.71-1.42; p-value=0.980). None of the covariates assessed
using the Cox regression had a significant influence
on OS.
Table 3 shows ORR results by treatment schedule and
by treatment drug. A total of 241 patients were evaluable
for response (117 and 121, respectively for the weekly
and the 3-weekly schedule, and 117 and 121, respectively
for the docetaxel and paclitaxel treatment group). In the
comparison between treatment schedules, the ORR was
significantly higher in the weekly treatment schedule
compared to the 3-weekly treatment schedule (odds
ratio; 0.504; 95% CI: 0.299-0.850; p-value=0.010) from
the logistic regression model adjusted for covariates.
No statistically significant differences were observed in the
comparison between treatment drugs (p-value=0.639).
In each treatment arm, there was a substantial reduc-
tion (i.e., >50% overall) in the number of patients who
completed the QoL questionnaire at the post therapy
visit when compared to those obtained at the beginning
of the treatment. Therefore, the results (data not shown)
are of poor reliability.Safety
A total of 3 patients were randomized but not treated
(1 in the docetaxel 3-weekly group and 2 in the pacli-
taxel 3-weekly group) and were excluded from the
safety population (238 patients). Overall, treatment-
emergent adverse events (TEAEs) were reported in
224 patients (94.1%) while 37 patients (15.5%) experi-
enced at least one treatment-emergent serious adverse
event (TESAE). Six patients (2.5%) died due to adverse
events. Chemotherapy-related TEAEs and TESAEs were
reported in 218 (91.6%) and 17 (7.1%) patients, respectively.
Grade 3/4 toxicities were reported in 168 (70.6%) subjects.
Twenty-two (9.2%) patients discontinued the study due
to TEAEs, while 14 patients (5.9%) were without
TEAEs. These results stratified by treatment drugs and
schedule are presented in Table 4.
Grade 3/4 toxicities occurred in 69.2% and in 71.9% of
patients receiving docetaxel and paclitaxel, respectively,
and in 65.8% and in 75.2%, in the weekly and 3-weekly
regimen, respectively. As shown in Table 5, neutropenia
(55.6% and 52.1% for docetaxel and paclitaxel group,
respectively, and 45.3% and 62.0% for weekly and 3-weekly
schedule, respectively) and leucopoenia (18.8% and 14.0%
Figure 3 Results of time-to-progression by treatment regimen (gemcitabine+docetaxel vs. gemcitabine+paclitaxel). Number of patients
still at risk for 3-weekly (1) and weekly (2) treatment regimen are reported above the X axis.
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and 21.5% for weekly and 3-weekly schedule, respectively)
were the most frequent grade 3/4 toxicities.
Discussion
Both gemcitabine/docetaxel and gemcitabine/paclitaxel
are active regimens for metastatic breast cancer but it
was unclear which of the two combinations has the
more favourable efficacy and safety profile. Furthermore,
it was unclear whether a weekly schedule would prove
more active and/or less toxic than the standard 3-weekly
schedule [6]. In fact, the lower doses and shorter infu-
sion times used with weekly dosing should minimize
bone marrow suppression and other toxicities associated
with standard 3-weekly schedules, while maintaining the
dose intensity necessary for anti-tumour activity.
This study was designed to address important infor-
mation on these issues choosing dosages of combined
drugs based on the information available at the time the
study was designed in order to maximise the effect of
each drug combination (except for the weekly combin-
ation of Paclitaxel and Gemcitabine, for which a lower
dose was chosen in favour of a better haematological
toxicity profile). Though, the slow accrual rate in the
trial prevented the completion of the planned patients’
enrolment within a reasonable time. An interim futilityanalysis was performed, and it was concluded that there
were neither scientific nor ethical reasons to continue en-
rolling patients for an additional 2-3 years, and as a result,
the study was terminated prematurely, before the planned
sample size population was reached. Therefore, the results
obtained from these analyses should be interpreted with
caution.
There was no statistically significant difference in the
primary study endpoint, TTP, between the treatment regi-
mens and the treatment schedule based on the analysed
data. The median TTP was 7.74 and 7.80 months for
patients treated with docetaxel plus gemcitabine and
paclitaxel plus gemcitabine, respectively. Median TTP
for patients treated with the weekly schedule and the
3-weekly schedule was 8.33 and 7.51 months, respect-
ively. In any case, no difference was observed between
the four treatment arms. Therefore, the two doublets
were similarly effective in TTP, while it was marginally,
although not significantly, prolonged with the weekly
regimen compared to the 3-weekly schedule.
The difference in OS between the treatment schedules
was significant neither by treatment schedule nor by
treatment regimen, despite being marginally prolonged
with paclitaxel.
Although the study was not designed or powered to
detect statistical difference in the secondary endpoints,
Figure 4 Results of time-to-progression by treatment arm (gemcitabine+docetaxel vs. gemcitabine+paclitaxel). Number of patients still
at risk for each treatment arm (1 - Arm A: docetaxel and gemcitabine 3 weekly; 2 - Arm C: docetaxel and gemcitabine weekly 3 - Arm B: paclitaxel and
gemcitabine 3 weekly; 4 - Arm D: paclitaxel and gemcitabine weekly) are reported above the X axis.
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3-weekly arm. However, no significant difference in ORR
between the treatment regimens was observed.
A recent paper [7] reported that the addition of
Gemcitabine to docetaxel failed to prove any clinically
meaningful benefit, given that no significant changes in
OS were detected as compared to the taxane group.Table 3 Results of ORR by treatment schedule (Weekly vs. 3-We
gemcitabine+paclitaxel)
Treatment schedule
Weekly 3-weekly
(N = 117) (N = 121)
N (%) N (%)
Complete response (CR) 8 (6.8) 7 (5.8)
Partial response (PR) 51 (43.6) 34 (28.1)
Stable disease (SD) 28 (23.9) 50 (41.3)
Progressive disease (PD) 25 (21.4) 16 (13.2)
Not available 1 (0.9) 2 (1.7)
Not assessed 4 (3.4) 12 (9.9)
ORR (CR + PR) 59 (50.4) 41 (33.9)
Odds Ratio (95% CI); p value 0.504 (0.299-0.850); 0.010
CI: Confidence Interval, ORR: Overall Response Rate; unadjusted odds ratio are preseAlthough our study was not designed to compare double
agents vs single agent therapy, it is worth to note that
the study from Nielsen and co-worker was not powered
to detect a benefit in survival. On the other hand, the
combination Gemcitabine-Docetaxel showed increased
TTP as compared to docetaxel only. With more caution,
Qi et al [8] in the recently published metanalysis aimingekly) and by treatment drug (gemcitabine+docetaxel vs.
Treatment drug
Gemcitabine + docetaxel Gemcitabine + paclitaxel
(N = 117) (N = 121)
N (%) N (%)
6 (5.1) 9 (7.4)
45 (38.5) 40 (33.1)
38 (32.5) 40 (33.1)
21 (17.9) 20 (16.5)
1 (0.9) 2 (1.7)
6 (5.1) 10 (8.3)
51 (43.6) 49 (39.8)
0.882 (0.523-1.488); 0.639
nted in the table.
Table 4 Summary of TEAEs and TESAEs in the four groups
Arm A Arm B Arm C Arm D
(N=59) (N=62) (N=58) (N=59)
N (%) N (%) N (%) N (%)
TEAEs:
Subject with at least one TEAE 57 (96.6) 58 (93.5) 53 (91.4) 56 (94.9)
Subject discontinued the study due to TEAE 4 (6.8) 4 (6.5) 6 (10.3) 8 (13.6)
Subjects with at least one chemotherapy-related TEAE 56 (94.9) 57 (91.9) 50 (86.2) 55 (93.2)
Subjects without TEAE 2 (3.4) 4 (6.5) 5 (8.6) 3 (5.1)
TESAEs:
Subject with at least one TESAE 9 (15.3) 10 (16.0) 7 (12.1) 11 (18.6)
Subjects with at least one chemotherapy-related TESAE 5 (8.5) 4 (6.5) 3 (5.2) 5 (8.5)
Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with
weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.
TEAE: Treatment-emergent Adverse Events, TESAE: Treatment-emergent Serious Adverse Events.
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MBC setting, report that the role of combination ther-
apy in MBC setting is still unclear, although combination
chemotherapy offers significant improvement in ORR
and PFS.
Toxicity was acceptable and was consistent with the
known safety profile of taxanes [9]. Grade 3/4 toxicities
rates were similar with docetaxel and paclitaxel (69.2%
and 71.9% of patients, respectively), and showed a higher
trend in the 3-weekly (75.2%) than in the weekly sched-
ule (65.8%). Neutropenia was the most common grade
3/4 toxicity, with lower rates for the weekly (45.3%) than
for the 3-weekly (62.0%) schedule, and small differences
between treatment regimens (55.6% and 52.1% for docetaxel
and paclitaxel group, respectively).
Although caution should be used in the interpretation
of these data, the use of a weekly schedule might beTable 5 Summary of most common grade 3 and grade 4 toxic
in any group)
Arm A Arm B
(N=59) (N=62)
G3 G4 G3
Neutropenia 24 (40.7) 22 (37.3) 22 (35.5) 7
Leukopenia 15 (25.4) 1 (1.7) 7 (11.3)
ALT increased 1 (1.7) 0 (0.0) 5 (8.1)
Diarrhoea 0 (0.0) 2 (3.4) 0 (0.0)
Myalgia 0 (0.0) 0 (0.0) 4 (6.5)
Alopecia 4 (6.8) 0 (0.0) 0 (0.0)
Hepatotoxicitya 0 (0.0) 0 (0.0) 1 (1.6)
Asthenia 4 (6.8) 0 (0.0) 3 (4.8)
Fatigue 3 (5.1) 0 (0.0) 3 (4.8)
Data are number (%) of patient; G = CTC Grade.
aALT are included in hepatotoxicities, but were separately reported by different stu
Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and g
weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.associated with a lower toxicity trend, with a better
maintenance of dose intensity and possibly with a better
tumour response compared to 3-weekly regimen, whilst
no differences between treatment schedules were ob-
served in the primary study endpoint of time to tumour
progression and no differences between drug treatments
were observed in safety and efficacy.
Moreover, the results of this study confirm data from
various studies supporting weekly taxane dosing as an
active regimen in MBC, even in heavily pretreated, re-
fractory disease and in elderly patients or those with
poor performance status [9]. It is reasonable hypothesize
that results obtained with the weekly schedule might
be driven by paclitaxel. In fact, it has been previously
reported that weekly administration of paclitaxel has
superior efficacy over the three weekly schedule coupled
with different toxicity profile [6,10] while weekly docetaxelities in the four groups (i.e., reported in ≥5% of patients
Arm C Arm D
(N=58) (N=59)
G4 G3 G4 G3 G4
(11.3) 15 (25.9) 4 (6.9) 23 (39.0) 11 (18.6)
3 (4.8) 6 (10.3) 0 (0.0) 6 (10.2) 1 (1.7)
0 (0.0) 8 (13.8) 0 (0.0) 6 (10.2) 0 (0.0)
0 (0.0) 4 (6.9) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
0 (0.0) 1 (1.7) 0 (0.0) 1 (1.7) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0) 3 (5.1) 0 (0.0)
0 (0.0) 5 (8.6) 0 (0.0) 6 (10.2) 1 (1.7)
0 (0.0) 3 (5.2) 0 (0.0) 4 (6.8) 0 (0.0)
dy investigators.
emcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with
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http://www.biomedcentral.com/1471-2407/13/164schedule proved to be at least as efficacious as tree weekly
schedule [6,11]. However, a recent review has concluded
that use of paclitaxel in advanced BC given in a weekly
regimen gives overall survival advantages compared with
the standard every three weeks regimen [12].
Conclusions
Despite the limitation due to its premature interruption,
the present study suggests that weekly administration
of a taxane, particularly paclitaxel, in combination with
gemcitabine is an active regimen for MBC, and might
be associated with a better tumour response as com-
pared to the 3-weekly schedule.
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